RenovoRx announces publication of data related to TAMP platform

RenovoRx announced a publication of positive early-stage clinical data relating to RenovoRx’s Trans-Arterial Micro-Perfusion, TAMP, therapy platform in the international peer-reviewed journal, The Oncologist. The scholarly article titled, “Treatment of Locally Advanced Pancreatic Cancer Using Localized Trans-Arterial Micro Perfusion of Gemcitabine: Combined Analysis of RR1 and RR2,” is a publication of early-stage clinical data, primarily procedure safety, overall survival, and evaluation of factors associated with OS, in LAPC patients undergoing TAMP from the foundational studies conducted by the Company. The studies included the intra-arterial administration of gemcitabine utilizing the TAMP read in an early Phase I/II dose escalation safety study and acquired data from a post-marketing post-treatment observational registry study. The lead author, Hassan Hatoum, MD, is an oncologist and hematologist at the University of Oklahoma Health Sciences Center.